Table 1.
Demographic Characteristics of the Study Population
| Characteristic at study enrollment | N (%) | Mean (SD) |
|---|---|---|
| Country | ||
| Argentina | 71 (6.9) | |
| Brazil | 712 (69.1) | |
| Mexico | 148 (14.4) | |
| Peru | 78 (7.6) | |
| Jamaica | 22 (2.1) | |
| Age (years) | 5.9 (3.7) | |
| Gender | ||
| Female | 550 (53.3) | |
| Male | 481 (46.7) | |
| HIV viral load (copies/ml) | ||
| >400 | 661 (64.4) | |
| ≤400 | 365 (35.6) | |
| CD4 count (cells/mm3) | ||
| <200 | 35 (3.4) | |
| 200–499 | 168 (16.5) | |
| ≥500 | 815 (80.1) | |
| CD4 percent | ||
| <15% | 88 (9.5) | |
| 15–24% | 256 (27.7) | |
| ≥25% | 579 (62.7) | |
| ARV regimen | ||
| No ARVs | 206 (20.0) | |
| NNRTI-containing regimen, no PIs | 178 (17.3) | |
| PI-containing regimena | 542 (52.6) | |
| Other ARV regimen | 105 (10.2) | |
| CDC disease classification | ||
| N | 115 (11.2) | |
| A | 245 (23.8) | |
| B | 316 (30.7) | |
| C | 352 (34.2) | |
| Duration of ARV use (years) | 3.5 (2.9) | |
| HIV RNA (log10 transformed) | 3.5 (1.4) | |
a
Of the 542 chlidren receiving combination therapy containing a PI, 265 (48.9%) were receiving a regimen containing lopinavir/ritonavir, seven (1.3%) were receiving indinavir and none atazanavir; two patients received TDF with lopinavir/ritonavir.
SD, standard deviation; ARV, antiretroviral; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF, tenofovir disoproxil fumarate.